’Kanarb Family’ Recorded 141.8 Billion Sales Last Year, “The Most Prescribed Domestic New Drug”
Based on the UBIST data
Korean new hypertension drug 'Kanarb’ family expands prescriptions in Mexico.
Boryung held the 'Congreso Anual de Cardiología Intervencionista (CADECI)' in Mexico on February 23rd.
The company also signed a memorandum of understanding (MOU) with local partner Stendhal for the local launch of Dukarb Plus within the year.
Dukarb Plus is one of ‘Kanarb’-based combination therapies.
In Mexico, Kanarb (locally known as Arahkor) was launched in 2014, followed by Kanarb Plus (Di-Arahkor) in 2016, Dukarb (Arahkor Duo) in 2019, and Tubero (Arahkor Pre) in 2020.
Kanarb family recorded sales of 141.8 billion won (based on the data by the drug market research firm UBIST) in Korea last year.
It was ranked at top in terms of the prescription volume among Korean new drugs.
Mr. Jang Doohyun, CEO of Boryung said, "The Kanarb family, which is the No. 1 prescribed new drug in Korea, has also been growing steadily in the Mexican market and is considered an exemplary case of entry into the Latin American pharmaceutical market. We will strengthen our cooperation with Stendhal and increase our market share in Mexico through expansion of Kanarb's line-up."
[WIKI KOREA=Cho Pil Hyun, Staff Reporter]